# Mercury Labs (NSE: MERCURYLAB) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/MERCURYLAB · Pivot · prices to 22 Oct 2026

With a market capitalisation of ₹102 Cr, it ranks 2667th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.

Its return on equity was 5.9% in FY25. Promoters held 73.66% of the company as of 30 Jun 2026.

## Key numbers

| Metric | Value |
| --- | --- |
| Market cap | ₹102 Cr |
| ROE | 5.9% (FY25) |
| ROCE | 8.8% (FY25) |
| Debt to equity | 0.08 |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY25 | ₹75 Cr | ₹3 Cr |
| FY24 | ₹76 Cr | ₹6 Cr |
| FY23 | ₹75 Cr | ₹6 Cr |
| FY22 | ₹58 Cr | ₹4 Cr |
| FY21 | ₹69 Cr | ₹5 Cr |
| FY20 | ₹57 Cr | ₹3 Cr |

## Shareholding (30 Jun 2026)

- Promoters: 73.66%
- Non-institutions: 26.34%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [Vaishali Pharma](https://app.pivotnow.in/stock/VAISHALI) | ₹7.49 | ₹101 Cr | 124.8 | — |
| [Concord Drugs](https://app.pivotnow.in/stock/CONCORD) | — | ₹101 Cr | — | — |
| [Denis Chem Lab](https://app.pivotnow.in/stock/DENISCHEM) | — | ₹101 Cr | — | — |
| [Fortis Malar](https://app.pivotnow.in/stock/FORTISMLR) | — | ₹97 Cr | — | — |
| [Raaj Medisafe](https://app.pivotnow.in/stock/RAAJMEDI) | — | ₹97 Cr | — | — |
| [KHFM HOSPITALIT](https://app.pivotnow.in/stock/KHFM) | ₹40.90 | ₹95 Cr | — | — |

## Questions and answers

### What is the market cap of Mercury Labs?

Mercury Labs' market capitalisation is ₹102 Cr (₹102 Cr) at the 22 Oct 2026 close, ranking 2667th among the NSE companies Pivot tracks.

### What is the ROE and ROCE of Mercury Labs?

Return on equity was 5.9% in FY25 and return on capital employed was 8.8% in FY25 (standalone figures).

### Is Mercury Labs a debt-free company?

No. Mercury Labs' debt-to-equity ratio was 0.08 in FY25, with total debt of ₹3 Cr.

### What is the shareholding pattern of Mercury Labs?

As of 30 Jun 2026: promoters 73.66%, non-institutions 26.34%.

### Who are Mercury Labs' competitors?

The listed Pharma & Healthcare companies closest to Mercury Labs by market cap are Vaishali Pharma, Concord Drugs, Denis Chem Lab, Fortis Malar, Raaj Medisafe and KHFM HOSPITALIT.

### Is Mercury Labs a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out Mercury Labs' price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on MERCURYLAB against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.